In recent years, mesenchymal stem cells have become the foundational technology for many cell products. Mesenchymal stem cells are pluripotent progenitor cells with the potential for multidirectional differentiation, which are able to migrate to sites of inflammation and exert effective immunosuppressive and anti-inflammatory effects through lymphocyte interactions associated with innate and adaptive immune systems.
Searches of ClinicalTrials.gov show that there are currently more than 1,300 clinical trials related to mesenchymal stem cells, involving multisystem diseases, including immune system diseases, digestive system diseases, nervous system diseases, respiratory diseases, endocrine system diseases and so on.
Up to now, a total of 14 new mesenchymal stem cell drugs have been approved for listing worldwide, a total of 21 new mesenchymal stem cell drugs in mainland China have been approved for clinical approval, and more than 30 clinical trial applications for new mesenchymal stem cells have been accepted.
14 new drugs listed in the world
21 new drugs of mesenchymal stem cells in China were approved
3 Continents received applications for the development of new drugs for mesenchymal stem cells
Summary: Mesenchymal stem cells have unique advantages, including availability, expansion, portability, etc., coupled with their low immunogenicity, immunomodulatory functions and other biological characteristics, such stem cells are considered to be a very promising type of stem cell therapy.
In recent years, countries are accelerating the clinical transformation process of mesenchymal stem cell products. The marketing process of mesenchymal stem cell related products has shown a new speed. This means that more patients will be able to use mesenchymal stem cell therapy products.